First Italian outbreak of VIM-producing Serratia marcescens in an adult polyvalent intensive care unit, August-October 2018: A case report and literature review

Table 1 Antibiotic susceptibilities, in accordance with the European Committee on Antimicrobial Susceptibility Testing of VIM-producing Serratia marcescens isolates with the date and first site of identification

	MIC (μg/mL)
AMK	≤ 4	8	≤ 4	≤ 4
AMC	> 32/2	> 32/2	> 32/2	> 32/2
AMP	> 8	> 8	> 8	> 8
FEP	> 8	> 8	> 8	> 8
CTX	> 4	> 4	> 4	> 4
CAZ	> 8	> 8	> 8	> 8
CIP	1	> 1	0.5	0.5
CST	> 4	> 4	≤ 1	≤ 1
ETP	> 1	> 1	> 1	> 1
FOF	≤ 32	64	≤ 32	≤ 32
GEN	> 4	> 4	4	4
IPM	> 8	> 8	> 8	> 8
LVX	2	> 2	1	≤ 0.5
MEM	> 8	> 8	> 8	8
PIP	> 16	> 16	> 16	> 16
TZP	> 16/4	> 16/4	> 16/4	> 16/4
TGC	> 2	> 2	> 2	> 2
TOB	> 4	> 4	> 4	> 4
SXT	> 4/76	> 4/76	> 4/76	> 4/76
Date	Aug, 1	Aug, 17	Sep, 20	Sep, 24
Site	Blood	Blood	RS	RT

AMC: Amoxicillin-clavulanic acid; AMK: Amikacin; AMP: Ampicillin; CAZ: Ceftazidime; CIP: Ciprofloxacin; CST: Colistin; CTX: Cefotaxime; ETP: Ertapenem; FEP: Cefepime; FOF: Fosfomycin; GEN: Gentamicin; IPM: Imipenem; LVX: Levofloxacin; MEM: Meropenem; PIP: Piperacillin; RS: Rectal swab; RT: Respiratory tract; SXT: Trimethoprim-sulfamethoxazole; TGC: Tigecycline; TOB: Tobramycin; TZP: Piperacillin-tazobactam.